title: Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis.
abstract: OBJECTIVE
  Currently, surgical treatment of hepatocellular carcinoma in patients with cirrhosis is not clearly defined. The objective of this study was, in patients with cirrhosis with hepatocellular carcinoma, to compare liver resection to transplantation assessed by patient survival and to determine whether the tumor recurrence might be influenced by prognostic factors.
  
  
  METHODS
  We have gathered all the available data from six French Medical Universities, for 215 patients with cirrhosis with hepatocellular carcinoma surgically treated either by liver resection (102) or by transplantation (113).
  
  
  RESULTS
  The overall 5-year survival rate was similar in the transplantation group and in the resection group (32% vs. 31%, p=0.7). However, the 5-year survival rate without recurrence was higher in the transplantation group than in the resection group (60% vs. 14%, p<0.001). Three independent prognostic factors influenced significantly the survival without recurrence: the surgical treatment by transplantation (p<0.001), the number of tumors (p<0.01) and the tumor size (p<0.001). With these factors we defined a prognostic index (Ip) which allowed assessment of the probability of survival without recurrence: Ip= (Xie. x 1.41)+(Nbr T. x 0.19)+(Size TV. x 0.16); Xie=surgical treatment (Xie=0 if transplantation, Xie=1 if resection), Nbr.T. and Size TV.=number of tumors and size of the most voluminous tumor, respectively, according to the histologic study.
  
  
  CONCLUSIONS
  These results and this prognostic index are encouraging for liver transplantation as treatment of hepatocellular carcinoma in selected patients with cirrhosis.
authors.affiliation: Service de Chirurgie Digestive et Unité de Transplantation, Centre Hospitalier Universitaire, Toulouse, France.
authors.forename: J
authors.initials: J
authors.lastname: Michel
authors.forename: B
authors.initials: B
authors.lastname: Suc
authors.forename: F
authors.initials: F
authors.lastname: Montpeyroux
authors.forename: S
authors.initials: S
authors.lastname: Hachemanne
authors.forename: P
authors.initials: P
authors.lastname: Blanc
authors.forename: J
authors.initials: J
authors.lastname: Domergue
authors.forename: J
authors.initials: J
authors.lastname: Mouiel
authors.forename: C
authors.initials: C
authors.lastname: Gouillat
authors.forename: C
authors.initials: C
authors.lastname: Ducerf
authors.forename: J
authors.initials: J
authors.lastname: Saric
authors.forename: Y P
authors.initials: YP
authors.lastname: Le Treut
authors.forename: G
authors.initials: G
authors.lastname: Fourtanier
authors.forename: J
authors.initials: J
authors.lastname: Escat
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002423:Cause of Death; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D017052:Hospital Mortality; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011336:Probability; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors